Angiosarcoma carries one of the most challenging prognoses in oncology, with five-year overall survival hovering around 30 to 40 percent across large studies and a median survival often measured in months rather than years. But that single number obscures enormous variation. A person with a small, localized tumor that can be completely removed surgically faces a fundamentally different outlook than someone diagnosed with visceral or metastatic disease, where median survival can drop to single digits. Understanding where the numbers come from, and which factors push the odds in either direction, matters for anyone trying to make sense of this diagnosis.
The Baseline Numbers
Angiosarcoma is a rare cancer of the cells lining blood vessels, accounting for roughly one to two percent of all soft tissue sarcomas. It can appear almost anywhere in the body, though the head, neck, and scalp are the most common sites, followed by the breast, liver, and heart.1PubMed Central. Current understanding of angiosarcoma: disease biology and evolving treatment A large U.S. study covering nearly 20,000 patients diagnosed between 2001 and 2020 found that about 72 percent of cases were cutaneous, subcutaneous, or breast angiosarcomas, while about a quarter were visceral.2JAMA Network Open. Incidence and Presenting Characteristics of Angiosarcoma in the US, 2001-2020 The typical patient is older, with a median age at diagnosis around 70 or 71, and incidence rises steeply with advancing age.3Scientific Reports. Incidence and site specific characteristics of angiosarcoma in Japan using a population-based national cancer registry from 2016 to 2019
A 25-year single-institution review reported a five-year overall survival of 40 percent and a median survival of 16 months for all patients combined. That study also highlighted what may be the single most important prognostic divider: patients who already had metastatic disease at the time of diagnosis had a median survival of just three months and zero percent five-year survival, compared with more than 60 months and 60 percent five-year survival in those with localized tumors.4PubMed Central. Angiosarcoma Outcomes and Prognostic Factors: A 25-Year Single Institution Experience A large SEER database analysis of head and neck angiosarcomas found a five-year overall survival of about 27 percent, though the five-year disease-specific survival, which counts only deaths from the cancer itself rather than all causes, was closer to 48 percent.5PubMed Central. Characteristics and Prognosis of Primary Head and Neck Angiosarcomas: A Surveillance, Epidemiology, and End Results Program (SEER) Analysis of 1250 Cases The gap between those two numbers reflects the fact that many patients are elderly and face competing health risks.
Why Location Changes the Outlook So Dramatically
More than perhaps any other cancer, angiosarcoma’s prognosis is tied to where in the body it appears. The biology of the tumor may be similar across sites, but the ability to detect it early, remove it surgically, and keep it from recurring varies enormously.
Scalp and face angiosarcomas are the most common subtype and carry a middling prognosis. A Mayo Clinic series reported a five-year overall survival of 38 percent and a median survival of about 25 months.6JAMA Otolaryngology–Head & Neck Surgery. Angiosarcoma of the Scalp and Face: The Mayo Clinic Experience However, scalp tumors specifically are harder to control locally than those on the face or other sites. One radiotherapy study found that five-year local control for scalp angiosarcomas was just 18 percent, versus 60 percent for non-scalp head and neck tumors and over 90 percent for breast primaries.7International Journal of Radiation Oncology, Biology, Physics. Angiosarcoma Treated With Radiotherapy: The University of Florida Experience The reason is partly anatomical: scalp angiosarcomas often spread diffusely beneath the skin in ways that are difficult to see and difficult to cut around.
Breast angiosarcoma includes both primary tumors and those that arise as a secondary cancer years after radiation therapy for a prior breast cancer. Radiation-associated breast angiosarcomas showed a three-year overall survival of about 84 percent in one comparative study, which was somewhat higher than the 68 percent seen in other radiation-associated sarcomas.8PubMed. A Comparison of Outcomes and Prognostic Features for Radiation-Associated Angiosarcoma of the Breast and Other Radiation-Associated Sarcomas Yet recurrence remains a persistent problem. Even after surgeons achieve clear margins, roughly two-thirds of patients with radiation-associated breast angiosarcoma develop a local recurrence, with a median time to recurrence of only about six months.9PubMed Central. Radiation-associated angiosarcoma after breast cancer: high recurrence rate and poor survival despite surgical treatment with R0 resection
Visceral angiosarcomas carry the worst outcomes. Primary liver angiosarcoma has a median survival as low as one month in some analyses, with a one-year survival of roughly 13 percent.10PubMed Central. Clinical characteristics of primary hepatic angiosarcoma outcomes: a SEER database analysis A separate institutional study found a somewhat longer median of six months in patients who received treatment, though the survival curve dropped steeply after that.11PubMed Central. Management Strategies and Outcomes in Primary Liver Angiosarcoma Cardiac angiosarcoma is equally grim; decades after the tumor was first described, complete surgical removal remains the best available option for symptom relief, with little hope of cure.12PubMed Central. Primary cardiac angiosarcoma – a review Visceral tumors are typically diagnosed late because early symptoms mimic more common conditions, and imaging findings can be nonspecific.
The Factors That Shape Individual Prognosis
Beyond tumor location, several measurable characteristics at diagnosis influence survival. A large prognostic model built from national data identified the following independent risk factors for worse overall survival after surgical resection:
- Age over 70: roughly double the hazard of death compared to younger patients.
- Tumor size: tumors between 3 and 7 centimeters carried about 1.6 times the risk, and those larger than 7 centimeters about 2.4 times the risk, compared to smaller tumors.
- High grade: grade 3 tumors had about 1.5 times the risk of lower-grade tumors.
- Positive surgical margins: microscopic residual disease roughly 1.6 times the risk; macroscopic residual disease more than three times the risk.
Head and neck primary site also independently predicted worse survival in that model.13PubMed. A prognostic model for resectable soft tissue and cutaneous angiosarcoma
Surgical margins deserve special emphasis because angiosarcoma tends to infiltrate surrounding tissue in subtle, finger-like projections that can be difficult to detect intraoperatively. In a study focused specifically on scalp angiosarcoma, patients with positive margins had more than four times the risk of recurrence and nearly five times the risk of death compared to those with clear margins.14PubMed. Prognostic significance of positive surgical margins for scalp angiosarcoma This is one reason surgeons often take wider excisions than the visible tumor would seem to require, and why radiation therapy is commonly added even after apparently complete removal.
How Angiosarcoma Is Treated
Treatment usually involves some combination of surgery, radiation, and chemotherapy, tailored to the tumor’s location, size, and whether it has spread. For localized disease, aggressive surgical removal combined with radiation for close or positive margins offers the best chance of long-term survival.15PubMed. Treatment and outcome of 82 patients with angiosarcoma Data from scalp and face angiosarcomas support this approach: patients treated with multimodality therapy (surgery plus radiation, sometimes with chemotherapy) had better five-year overall survival and recurrence-free survival than those treated with any single modality.6JAMA Otolaryngology–Head & Neck Surgery. Angiosarcoma of the Scalp and Face: The Mayo Clinic Experience Higher radiation doses also appear to improve local control, with doses above 66 Gy in standard fractions linked to significantly better outcomes in a multi-institutional Japanese study.16PubMed Central. Clinical Outcomes of Radiation Therapy for Angiosarcoma of the Scalp and Face: A Multi-Institutional Observational Study
For metastatic or unresectable disease, systemic chemotherapy is the mainstay. Weekly paclitaxel is one of the most commonly used agents. A phase II trial (the ANGIOTAX study) found a median time to progression of four months and a median overall survival of eight months with this regimen.17Journal of Clinical Oncology. Phase II Trial of Weekly Paclitaxel for Unresectable Angiosarcoma: The ANGIOTAX Study Doxorubicin, the traditional workhorse of sarcoma chemotherapy, performs similarly: a comparison of the two drugs in metastatic angiosarcoma found roughly equivalent efficacy, though paclitaxel produced higher response rates in cutaneous cases.18Cancer. Comparison of doxorubicin and weekly paclitaxel efficacy in metastatic angiosarcomas
Researchers have also tested adding bevacizumab, a drug that blocks blood vessel growth, to weekly paclitaxel. A randomized trial found that both arms were active, with six-month progression-free survival around 54 to 57 percent. But the combination arm added more toxicity, including one fatal side effect, without clearly improving outcomes. The investigators concluded the combination did not warrant further study.19Journal of Clinical Oncology. Paclitaxel Given Once Per Week With or Without Bevacizumab in Patients With Advanced Angiosarcoma: A Randomized Phase II Trial
Immunotherapy and the Search for Better Options
Immune checkpoint inhibitors are among the most promising new approaches being explored. A retrospective study of 25 patients treated with pembrolizumab, most of whom had metastatic disease and had already failed multiple prior treatments, reported an objective response rate of 18 percent and a disease control rate of 59 percent. Median progression-free survival was about six months.20PubMed. Clinical activity of checkpoint inhibitors in angiosarcoma: A retrospective cohort study A second single-center analysis of 35 patients found a median progression-free survival of roughly 12 weeks, with about 37 percent of patients progression-free at 16 weeks. Patients who received checkpoint inhibitors combined with other therapies and those with cutaneous head and neck disease tended to fare better.21PubMed Central. Clinical, genomic, and transcriptomic correlates of response to immune checkpoint blockade-based therapy in a cohort of patients with angiosarcoma treated at a single center
A smaller case series of seven patients was particularly striking: five of seven had partial responses at 12 weeks, and one patient achieved a complete response with an anti-CTLA-4 agent.22PubMed Central. Angiosarcoma patients treated with immune checkpoint inhibitors: a case series of seven patients from a single institution These numbers come from tiny, uncontrolled studies and should not be taken as proof that immunotherapy works well for most patients. But in a disease where options have historically been limited, even modest signals of activity get attention. Cutaneous angiosarcomas of the head and neck, which tend to be heavily sun-damaged and carry higher mutational burdens, may be particularly susceptible to immune-based strategies, though this remains an active area of research.
On the molecular side, laboratory work has shown that signaling pathways involved in blood vessel growth (VEGF) and cell proliferation (MAPK) are frequently active in angiosarcoma cells. Combining drugs that target both pathways shrank tumors more than either drug alone in preclinical models.23Scientific Reports. Combined VEGFR and MAPK pathway inhibition in angiosarcoma Whether this translates to clinical benefit in people remains to be seen, but it represents the kind of biology-driven approach that could eventually supplement or replace conventional chemotherapy.
Recurrence Patterns and What They Mean
One of the most difficult aspects of angiosarcoma is how often it comes back after treatment. A Danish nationwide cohort of cutaneous angiosarcoma found five-year risks of 40 percent for local recurrence and 41 percent for metastasis.24PubMed. Cutaneous angiosarcoma: Long-term outcomes and risk factors of local recurrence, metastasis and disease-specific mortality in a Danish nationwide cohort A single-center European study reported even higher local recurrence rates, exceeding 60 percent in both primary and secondary angiosarcomas.25BMC Cancer. Low overall survival after treatment for angiosarcoma: a single-centre retrospective observational cohort study of 64 patients These recurrences often come quickly. In radiation-associated breast angiosarcoma, the median time to local recurrence after clear-margin surgery was just six months.9PubMed Central. Radiation-associated angiosarcoma after breast cancer: high recurrence rate and poor survival despite surgical treatment with R0 resection
Crucially, recurrence is not always a death sentence. The same breast angiosarcoma study found that patients whose recurrence could be surgically removed survived a median of 34 months afterward, compared with just six months for those whose recurrence was inoperable. This underscores the importance of close surveillance after initial treatment. Many oncologists follow angiosarcoma patients with imaging every few months for the first several years, precisely because catching a recurrence early enough to re-operate can meaningfully extend life.
MYC Amplification and Molecular Markers
Researchers have started identifying molecular features that predict how aggressive a given angiosarcoma will be. One of the most clinically relevant is MYC gene amplification, which is especially common in radiation-associated angiosarcomas of the breast. In one study, MYC amplification was linked to dramatically worse overall survival, with a hazard ratio above 20 in multivariate analysis after adjusting for tumor size.26PubMed Central. The impact of MYC amplification on clinicopathologic features and prognosis of radiation-associated angiosarcomas of the breast A separate study confirmed the association, showing that patients with MYC-amplified secondary angiosarcomas had significantly worse survival.27PubMed. Angiosarcoma and atypical vascular lesions of the breast: diagnostic and prognostic role of MYC gene amplification and protein expression
MYC testing also helps pathologists tell the difference between a true secondary angiosarcoma and an atypical vascular lesion, a benign-looking growth that can appear in irradiated skin and sometimes mimics low-grade angiosarcoma under the microscope. While MYC amplification is highly specific for secondary angiosarcoma, it is not very sensitive, meaning a negative result does not rule the diagnosis out. The practical takeaway for patients is that molecular testing can provide prognostic information beyond what traditional staging offers, and in some cases can influence how aggressively treatment is pursued.
Known Causes and Risk Factors
Most angiosarcomas have no clearly identifiable cause, but several established risk factors exist. Prior radiation therapy is one of the best-documented. Angiosarcomas can develop in previously irradiated tissue years or even decades after the original treatment, most commonly in the breast after radiation for breast cancer, though they can also arise in the chest wall, head, and neck after other cancers. Chronic lymphedema is another longstanding association, originally described in the arms of women after radical mastectomy.
For liver angiosarcoma specifically, occupational exposure to certain chemicals has been established as a cause. Workers with the highest cumulative exposure to vinyl chloride, a chemical used in plastics manufacturing, had a risk of liver angiosarcoma more than 70 times that of workers in the lowest exposure category.28Occupational & Environmental Medicine. Quantitative estimated exposure to vinyl chloride and risk of angiosarcoma of the liver and hepatocellular cancer in the US industry-wide vinyl chloride cohort: mortality update through 2013 Exposure to thorium dioxide (an obsolete radiological contrast agent) and arsenic has also been linked to hepatic angiosarcoma.29PubMed Central. Statistics and outlook of primary hepatic angiosarcoma based on clinical stage Modern workplace safety regulations have greatly reduced vinyl chloride exposure, but cases still emerge, often decades after the initial exposure because of the long latency period.
Racial Disparities in Outcomes
Survival statistics are not evenly distributed across populations. A single-institution analysis of head and neck cutaneous angiosarcoma found significant differences between Black and White patients. Although overall recurrence rates were comparable, Black patients experienced recurrences roughly twice as fast and had worse overall survival. White patients, by contrast, were more likely to develop distant metastases. The study was small, with only 34 patients, so the specific numbers should be interpreted cautiously, but the finding echoes a broader pattern in the prognostic modeling literature, where Black race independently predicted worse overall survival even after adjusting for tumor size, grade, and treatment.30PubMed Central. Racial Disparities In The Prognosis And Mortality Of Head And Neck Cutaneous Angiosarcoma – A Single Institution Analysis 13PubMed. A prognostic model for resectable soft tissue and cutaneous angiosarcoma The reasons for these disparities are not fully understood. Differences in access to specialized sarcoma centers, delays in diagnosis, and possible underlying biological variation have all been proposed, but none have been conclusively shown to explain the gap.
Predicting Survival More Precisely
Traditional cancer staging systems were designed for common tumors and do not always capture the factors that matter most in rare cancers. Researchers have developed angiosarcoma-specific nomograms, essentially point-based calculators that combine several variables to estimate an individual patient’s likelihood of survival at three and five years. One SEER-based nomogram incorporating age, race, tumor site, grade, size, stage, and treatment achieved a concordance index of about 0.74, meaning it correctly ranked pairs of patients by survival about 74 percent of the time. That outperformed the standard AJCC staging system, which scored around 0.61 to 0.66.31PubMed Central. Trends in the incidence, survival, and prognostic nomogram of angiosarcoma in the United States Other groups have built similar tools with comparable accuracy.32Scientific Reports. Prognostic nomograms for predicting overall survival and cancer-specific survival in patients with angiosarcoma, a SEER population-based study
These tools are not crystal balls. A concordance index of 0.74 means there is still meaningful uncertainty, and nomograms are built from population-level data that may not reflect an individual’s biology, response to treatment, or access to care. But they represent a more nuanced approach than simply citing the overall five-year survival rate, and some oncologists use them alongside clinical judgment when discussing prognosis with patients.
What Dog Cancer Research Might Tell Us
An unexpected source of insight into angiosarcoma comes from veterinary oncology. Dogs, particularly breeds like Golden Retrievers and German Shepherds, develop hemangiosarcoma at much higher rates than humans develop angiosarcoma. The two tumors originate from the same cell type, the vascular endothelium, and share similar clinical behaviors, including aggressive growth and a high tendency to metastasize.33PubMed Central. Hemangiosarcoma in dogs as a potential non-rodent animal model for drug discovery research of angiosarcoma in humans Molecular studies have confirmed that key signaling pathways and even specific mutations are conserved between canine hemangiosarcoma and human angiosarcoma.34PLOS ONE. Molecular subtypes in canine hemangiosarcoma reveal similarities with human angiosarcoma
Because canine hemangiosarcoma is so much more common than its human counterpart, clinical trials in dogs can enroll patients faster and test new treatments more efficiently. Several research groups are actively exploring whether drugs that show benefit in dogs with hemangiosarcoma could be fast-tracked for evaluation in human angiosarcoma patients.35Veterinary and Comparative Oncology. Identification of genomic alterations with clinical impact in canine splenic hemangiosarcoma This “comparative oncology” approach is still in its early stages, but it represents one of the more creative strategies for accelerating progress against a cancer too rare to study efficiently through conventional clinical trial pipelines alone.
Quality of Life During Treatment
Survival statistics understandably dominate conversations about angiosarcoma, but the toll of treatment on daily life is worth acknowledging. A large international observational study of patients with advanced soft tissue sarcomas, including angiosarcomas, measured health-related quality of life over the course of palliative chemotherapy. Overall quality-of-life scores dropped significantly during treatment, falling by a clinically meaningful margin regardless of whether the patient’s tumor responded to the drugs or continued to progress.36The Lancet (eClinicalMedicine). Health-related quality of life in patients with advanced soft tissue sarcomas treated with chemotherapy: results from an international observational cohort study Interestingly, angiosarcoma patients started treatment with higher baseline quality-of-life scores than most other sarcoma subtypes, but the decline over time was similar. For patients and families weighing the decision to pursue aggressive treatment, especially in the metastatic setting, understanding that chemotherapy carries a measurable quality-of-life cost even when it works is an important part of the picture. In some cases, particularly for elderly patients with visceral disease and limited treatment options, palliative care focused on symptom management may be the more appropriate path, a conversation best had with an oncologist who specializes in sarcomas.